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Abstract 
Introduction: Decision-analytic models play an essential role in informing healthcare resource allocation 
decisions; however, their value to decision makers will depend on model structures being clinically valid to 
determine cost-effectiveness recommendations. Clinician involvement can help modellers to develop clinically 
valid but straightforward structures, however, there is little guidance available on methods for clinician input to 
model structure. This study aims to provide an in-depth exploration of clinician involvement in structural 
development, highlighting key issues and generating recommendations to optimise practices.  
Methods: A qualitative study was undertaken with a range of modellers and clinicians working in different 
modelling contexts. In-depth interviews and case studies using observations were carried out to understand how 
clinicians are involved in model structural development and to identify problems and optimal approaches from 
informants’ perspectives.  
Results: Twenty-four interviews and two case studies were undertaken with modellers and modelling teams. 
Key issues included the number and diversity of clinicians contributing to structural development, potentially 
impacting the generalisability of structures, and problems with clinician understanding of important information 
to contribute to model pathways. Modellers and clinicians suggested that clinician training in modelling could 
enhance structural processes.  
Conclusions: Recommendations to optimise current practices include recruiting clinicians from a variety of 
backgrounds and using discussions between experts to develop valid and generalisable structures. Future 
research should focus on developing training materials for clinicians and finding ways to help modellers recruit 
clinicians from different settings. 
Key points 
• Clinician input to the development of decision-analytic model structures is important to ensure clinical 
validity; however, little guidance is available on optimal methods. 
• Key issues with clinician involvement in structural development include the generalisability of model 
structures, and clinician understanding of the information that it is important to contribute for the 
development of model pathways.  
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• This research recommends that modellers recruit or involve clinicians from a variety of backgrounds to 
achieve representative model pathways, and consider offering clinicians training in model development 
to enhance communication and structural processes.   
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1 Introduction 
Decision-analytic models play a key role in informing health technology assessment (HTA) and resource 
allocation decisions [1, 2]. Models provide a vehicle for economic evaluation and cost-effectiveness analysis, 
where the focus is on establishing incremental costs and consequences of competing interventions to inform 
decision-making [3]. An essential aspect of developing a model is ensuring that it is clinically valid and reflects 
real life, but also that it is straightforward to its users [4]. Model structures can therefore be more simplistic than 
the ‘real world’. The pathways or states contained in model structure should reflect the disease natural history 
[5-8] but also prioritise events where differences in the costs and outcomes between competing interventions are 
expected, and events that are likely to impact the model output [9,10]. Consulting with clinicians can help 
modellers to build straightforward but valid structures and ensure important events are captured. However, little 
guidance exists on clinician input to structural development, with current guidelines suggesting that clinicians 
should be consulted but offering limited insight into how this works in practice [8]. A recent synthesis of 
modelling guidelines ignored clinician involvement in structural development entirely [11].  
The benefits of using qualitative research to explore modelling activities have been advocated, with a view to 
using findings to make improvements to modelling practices [12]. A small number of empirical studies have 
used qualitative methods to generate recommendations for model-building, looking at clinician involvement in 
structural development as part of broader research [13-15]. Recommendations from these studies emphasised 
the importance of using clinical input to translate the disease area/decision problem into model structure, and for 
structural validation. These papers  suggested that clinicians should be involved early in structural development 
[15] and recommended the input of large numbers of clinicians [8] and clinicians from different backgrounds 
[13]. Two papers suggested methods for facilitating communication between modellers and clinicians, 
specifically non-technical terminology and structural diagrams to aid discussions [13, 14]. Although these 
recommendations are valuable, there has been no focused research to understand current practice and key issues 
with clinician involvement in structural development.  
This paper presents findings from a research study using in-depth qualitative methods to explore clinician 
involvement in structural development, aiming to highlight good practice and important areas for future 
research. Model structure is defined here as the representation of the health and economic consequences 
occurring when patient populations receive particular medical interventions [16]. 
2 Methods 
2.1 Overview  
This research used two phases of qualitative study to investigate clinician involvement in structural development 
from the perspectives of those involved [17]. In-depth interviews were used in the first phase to gather rich 
accounts of modellers’ processes for involving clinical experts [18]. The second phase used case study methods, 
specifically non-participant observation and semi-structured interviews, to gain comprehensive insight into 
structural development as it occurred [19]. Whilst observations demonstrated how modelling teams were 
involving clinicians, interviews captured reflections of informants on methods used. Both phases of the research 
were used together to generate key findings. 
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2.2 Sampling 
Modellers for in-depth interviews were sampled using purposive sampling, which focuses on the views of those 
able to provide in-depth knowledge of the topic of interest [19]. Sampling also aimed to capture variation in 
breadth of modeller experience, from two settings where economic modelling is integral to HTA: UK and 
Canada [20, 21]. Modellers approached included those working in academia, industry (for 
consultancies/pharmaceutical companies), and policy (institutes). The seniority of an informant (level of 
experience) was judged according to whether modellers worked mostly in a managerial capacity (senior), or on 
hands-on model development (junior). Snowball sampling, where existing informants suggest others to 
contribute to the research, provided access to non-academic and international informants [22]. Sampling 
continued until saturation; where no new insights were emerging from continued interviews [23]. 
Sampling for case studies involved selecting modelling teams to observe throughout a single model’s 
development, with those who could provide potentially different insights to enhance transferability of findings 
[24]. Sampling focused on teams who had a good reputation in model building and from whom we could make 
inferences about good modelling practices, which would be helpful to other modellers and settings [25]. Phase 
one informants were asked to recommend modelling teams who met these criteria, and a sub-sample were 
approached by the authors. 
2.3 Data collection 
In-depth interviews were conducted face-to-face [26]. Interviews followed a topic guide (Appendix 1) which 
was updated as new themes emerged. Open-ended, responsive questioning was adopted [27].   
Case study observation was undertaken of all face-to-face meetings and emails, and semi-structured interviews 
were conducted with modellers and clinicians at various time points throughout structural development. Most 
interviews were face-to-face, but some with clinicians were over the telephone. A topic guide was used, which 
included general questions and those specific to context observed.  
Meetings were audio-recorded, and notes were taken to report the primary author’s perceptions and thoughts 
[28].  Interviews in both phases were audio-recorded. 
2.4 Data analysis 
In-depth interviews were analysed by SH using methods of constant comparison, which requires new data to be 
continually compared with existing data to enhance understanding and develop key themes [29]. Interview 
transcripts were coded line-by-line and data were organised into themes and assigned a representative code [30]. 
Analysis was undertaken for batches of interviews and a coding structure was developed and applied to all 
transcripts, with codes continually updated for new data. Analytic accounts were created for each batch of 
interviews to compare informants’ comments, and later combined. A sub-sample of transcripts were double-
coded by JC. 
Case study data were analysed using Framework analysis; a matrix based analytic method where individual 
informants’ data (for example excerpts from interviews) are charted and organised into shared themes to 
synthesise findings [31]. Analysis began with a review of data, and notes taken of important and recurrent 
themes to generate a thematic framework [31]. This framework was applied to all case study materials and 
refined as themes emerged. Data were coded by line or passage using a qualitative software package, NVivo10. 
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Charts were created for each case study to organise excerpts from data collection according to key themes and 
the method by which they were generated.  
In presenting findings, all informants have been assigned identifiers starting M to indicate a modeller and C a 
clinician; clinical details of modelling activities are anonymised. The findings have been synthesised under four 
overarching themes which combine findings from both research phases: recruiting clinicians, number and 
background of clinicians, problems with clinician involvement and enhancing clinician involvement.  
3 Results 
3.1 Informant characteristics  
For phase one, 24 in-depth interviews were undertaken with a range of modellers, with varying experience noted 
within senior and junior groups (Table 1).  
For phase two, two case studies were undertaken. Case Study A (CSA) was within a UK university, with a 
junior and senior modeller and one clinician (C1) involved in the primary team. C1 was the Chief Investigator 
(CI) and was a specialist consultant with over ten years’ experience working for the National Health Service 
(NHS). C1 had no previous experience of modelling. The  model received ad-hoc input from another modeller 
and wider group of clinical collaborators and statisticians. Case Study B (CSB) was in a UK policy institute and 
the modelling team included a junior and senior modeller, and up to eleven clinical experts per meeting. The 
backgrounds of clinicians recruited to CSB varied in geographical area and clinical role. A subset of three 
clinicians were sampled for interview (C2-C4). All worked for NHS hospitals and had over ten years’ 
experience as a consultant in their respective specialisms. All also had some previous experience of health 
economics, with C3 having input to other models and C2 and C4 worked on research projects with a cost-
effectiveness element. Other members of the modelling team included information specialists, systematic 
reviewers and project managers. See Table 2 for case study characteristics. Table 3 contains a summary of the 
results.   
3.2 Recruiting clinicians for structural development  
Modellers interviewed in phase one discussed clinician recruitment, with a common scenario for UK academic 
modellers, and CSA, being that clinicians were CIs or co-applicants on a project requiring modelling expertise. 
The industry and policy modellers interviewed (including CSB) mostly reported recruiting clinicians to their 
own model-based projects, citing formal and established methods for doing so (including links through model 
clients and via public advertisements). However, the remaining academic modellers (UK and Canadian) 
described informal processes for recruitment, such as cold calling and pursuing links through colleagues. These 
modellers indicated that they had difficulty engaging clinicians, particularly when relying on clinicians for ad-
hoc input: 
M4 (interview, phase 1): “it’s often quite difficult to get a clinician’s time… if they have a lot of 
clinical time with patients it’s almost impossible...” 
In terms of a clinicians’ role, there was consensus across interviews and case studies that clinician input was 
required to inform model clinical pathways, and emphasis from some modellers around the importance of 
clinicians agreeing a final version of structure prior to running the model:  
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M24 (interview, phase 1): “I don’t do too much on [validation of] structure…if I’ve got sign off from 
the clinician…” 
3.3 Number and background of clinicians 
Numbers of clinicians involved in structural development varied for interview informants (Table 4), as they 
discussed involving between zero and twelve, with the most common scenario being two, but a quarter of 
informants discussing working with one. CSA and CSB involved one and up to eleven clinicians respectively. 
Numbers differed as those working in industry and policy involved greater numbers than those in academia, 
potentially due to different strategies for recruitment. Modellers suggested numbers could vary between projects 
and according to disease complexity and variation in healthcare practices: 
M9 (interview, phase 1): “... [Disease area] is where you have the biggest variation in clinical practice 
and I think you need bigger numbers because even within a hospital trust you’d see different practices 
in terms of current care…” 
A third of modellers interviewed discussed the importance of working with ‘key’ or senior clinicians, implying 
that it was likely to increase a model’s clinical validity and robustness to outside criticism:  
M13 (interview, phase 1): “You want as many leading people in the field as possible because hopefully 
you will have got all of the opinions out prior to [submission] …you’re not going to have some 
clinician turning up saying something different”  
3.4 Problems with clinician involvement 
3.4.1 Clinician numbers 
Although a quarter of modellers described instances of involving one clinician in structural development; 
modellers’ general opinion was that this would limit structural generalisability:  
M7 (interview, phase 1): “…you’re asking one person to make an assumption… in their experience it 
may be completely different than someone else’s…” 
M12 (interview, phase 1): “you could have a rogue, which has happened…one clinician view, fine, 
went to the board and they said ‘the way he treats patients is completely different’…” 
Issues with generalisability and clinician numbers were raised in CSA, as C1, being the only clinician involved 
in the primary team, struggled to decide on a representative care pathway, having worked in centres with 
different practices: 
C1 (observation, CSA): “…in [Location 1] the consultant would treat the [Test 2] result rather than… 
the symptoms …but in [Location 2] because we have [Test 1]… if we can find [Symptom 2] we will do 
[Minor surgery]”  
However, there were a small number of modellers who discussed problems with involving larger groups in 
structural development, specifically managing and incorporating multiple perspectives: 
M17 (interview, phase 1): “…things quickly get complicated because you end up with eight clinicians 
who have eight different views… and end up with an over-elaborate model…”  
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The issue of generalisability of clinician experience was rarely acknowledged, with only one interview 
informant (M8) and one case study (CSB) having discussed or observed recruiting clinicians from a range of 
backgrounds: 
M8 (interview, phase 1): “… an A and E nurse, a consultant…a surgeon…we try to get a big range of 
clinicians involved with the pathway…” 
3.4.2 Clinician understanding  
Most interview informants reported problems with receiving information from clinicians, as clinicians focused 
on the experiences of individuals rather than groups of patients when informing structural pathways:  
M11 (interview, phase 1): “this concept of ‘we are massively oversimplifying what happens in this 
disease and we’re assuming every patient is the same’, that’s quite difficult for clinicians” 
M14 (interview, phase 1): “the hard thing with clinicians is getting them to abstract because they see 
individuals, they don’t see a group” 
Many interview informants also commented on the tendency of clinicians to highlight uncommon and 
unrepresentative patient experiences when suggesting health states/pathways to include: 
M4 (interview, phase 1): “they'll talk about really rare events…that in their thirty years of experience 
they've witnessed once, and they'll suggest you put this in…” 
Similar tensions were observed within CSA, as C1 suggested that the experiences of a rare patient group should 
be incorporated, with the modeller conversely suggesting that this population should be excluded for not 
representing a common group: 
Observation, CSA: 
C1: “Include them…in the last six years…I have only seen one a year where they’ve had [Problem 3] 
and they’ve had [Major surgery], they’re a small proportion…”  
M26: “…we just want to be trundling along as if most people are the general case…although you’ve 
said include them I think we mean exclude them, because they’re such a minority…” 
However, a contrasting situation was observed in CSB, as clinicians appeared to consider it inappropriate to 
include a rarer clinical event in the structure due to lack of available evidence. The modeller subsequently 
implies that this event should be included because it is economically important and may impact the cost-
effectiveness analysis:   
Observation, CSB: 
M28: “Can those with a false positive diagnosis have [Treatment]…?” 
C4: “It could happen….”   
C5: “…I’ve certainly heard of a case…”   
C10: “I think on the basis of [finding] evidence you can say no….”   
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M28: “…but that box still needs to be explored to compare [Comparator C] against how many people 
would end up there with [Comparator B] or [Comparator A]”  
Other communication issues observed in the case studies included clinicians’ problems with interpreting the 
research and economic terminology used by modellers: 
Observation, CSA:  
M25: “are the utilities, after the surgery…”   
C1: “…sorry?”   
M25: “…if the person has [Major surgery], the utility might be different…”   
C1: “…the, what will be different sorry?” 
 M26: “…the quality of life…” 
3.5 Enhancing clinician involvement: recommendations emerging from the research 
3.5.1 Optimum number 
Observations from CSB suggested that discussions between multiple clinicians were valuable for identifying 
common and representative structural pathways, avoiding the generalisability issues observed with one clinician 
in CSA:  
Observation, CSB:  
C5: …[if] the [Comparator A test] is negative and I’ve got low…clinical suspicion, there’s a pathway 
back out the door…”  
C3: “…once you’ve [tested] someone for [Problem A], we are obliged to put them on a pathway…”   
C5: “… you always refer the patient into…follow-up?!”   
C9: “…. it varies from clinic to clinic…but  people get a second [test] even if they are asymptomatic…”   
C3: “I think the answer is ‘yes, a second [Comparator A test] gets done’…”  
Comments from clinicians in CSB advocated involving larger numbers and a diversity of clinical expertise, with 
discussions leading to increased confidence in the clinical validity and structural generalisability of model 
results: 
C2 (interview, CSB): “It’s clear from discussions around the table that things are very different across 
the country and …it’s…really important…in terms of validating the outcome…the strength and breadth 
of experience and geography of clinicians”  
C3 (interview, CSB): “If there are issues that you haven’t considered as a group that are pointed out 
after [the model has been published] it would undermine credibility…it’s important to have these 
discussions”  
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3.5.2 Clinician training 
Several modellers suggested offering clinicians training in structural development to enhance efficiency of 
structural processes, advocating the value of providing clinicians with information about clinically and 
economically important pathways/states to communicate: 
M24 (interview, phase 1): “…clinicians who have got training…just totally get it…they know which 
[health states/pathways] are a big deal and which ones…aren’t really going to influence results…” 
M25 (interview, CSB): “ …it is necessary for [clinicians] to understand…the health economics and 
mostly what drives the costs and what is important in the clinical effectiveness of the treatment…”  
The idea of training was supported by all clinicians interviewed, as each discussed their own struggles with 
understanding. Clinicians suggested that guidance from modellers on how models work, modelling terminology 
and expected contributions to structural development would be beneficial: 
C1 (interview, CSA): “…we could have a…brief in the beginning to explain health economics, what 
modelling is, and what they expect from us…”   
C2 (interview, CSB): “…a dictionary of terms…a glossary…‘this mean[s] this’”  
Clinicians commented on the preferred nature of training, suggesting interactive and distance learning were 
optimal.  
C3 (interview, CSB): “…interactive online training or a video…because then it would be something we 
could do in our own time…” 
Clinicians implied that regular education was important, suggesting that seeing updates of the model as it was 
developed would enhance understanding. This could help optimise clinical validity through regular checks, and 
aid clinicians with interpretations of results. A few modellers reflected that showing clinicians structural 
diagrams during development helped with engagement:  
C4 (interview, CSB): “…models are such an unfamiliar way of looking at information….I don’t 
[understand] the shape the model is taking…I suspect the finished product [is] going to take some 
explaining….” 
M13 (interview, phase 1): “…when you’re going through a model physically they [clinicians] get more 
involved…”  
However, there was resistance from a small number of modellers, who questioned the practicality of work 
required to develop and deliver training materials: 
M26 (interview, CSA): “….you don’t want to meet every clinical collaborator and sit down and tell 
them why [modelling is] needed…”  
4 Discussion 
4.1 Key findings 
This research has provided detailed insight into clinician involvement in structural development, highlighting 
key issues around clinician recruitment, numbers and generalisability, and clinician understanding. Information 
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was collected on numbers and backgrounds of clinicians involved in current processes, demonstrating the 
average number to be two, but highlighting the experiences of several modellers who had involved only one. 
This included the observation of a single clinician in Case Study A, who struggled to decide on representative 
clinical pathways to inform model structure. Only one of the case studies and one modeller interviewed 
discussed recruiting clinicians from different clinical/geographical backgrounds. These findings raise issues 
around the generalisability of model structures, particularly when compared to approaches used to elicit 
evidence parameter values from experts, as these studies recruit/recommend greater numbers and varied samples 
of clinicians to reflect differences in clinical practices and avoid bias [32, 33]. Further, several modellers in this 
research discussed being approached for participation by clinicians with existing projects (academic modellers) 
or using established contacts to recruit experts (industry modellers), with emphasis on speaking to leading and 
senior clinicians. However, this approach could potentially lead to bias in similar groups of clinicians 
continually being asked to contribute, and the under representation of experiences of lesser known and junior 
clinicians.  
Modellers reported and were observed having difficulties with retrieving required information from clinicians, 
as clinicians were unaware of the importance of including events in the structure which are likely to impact cost-
effectiveness. Clinicians had problems understanding how model structures were developed and with 
interpreting the economic and research terminology used, with clinicians and modellers supporting training for 
clinicians. Although we have not identified any studies advocating clinician training in structural development; 
its importance has been emphasised in the expert elicitation literature, suggesting that experts will give more 
confident and accurate answers if they know the purpose and processes behind the tasks they are given [32]. 
These findings collectively support the value of recommendations to enhance clinician involvement in structural 
development.  
4.2 Strengths and limitations 
This research extends insight into clinician involvement in structural development significantly, based on in-
depth qualitative study with a broad sample of modellers. Although there were synergies between the findings 
generated and those of similar studies, including the importance of effective communication and varied clinical 
perspectives [13-15], issues around generalisability and the importance of clinician training have not previously 
been emphasised. A comprehensive sampling strategy was employed to include the perspectives of a range of 
modellers to ensure findings from this research could be generalisable to multiple modelling contexts and 
relevant to a variety of modellers. The research also includes the perspectives of clinicians on structural 
development, which have not been investigated previously. 
The work was limited by only having resources to conduct two case studies, both in the UK setting. Although 
the case study research was extensive, further work could benefit from widening the case studies to explore 
models conducted within industry, in other country settings or with smaller/lesser known modelling teams. It is 
possible that the work is also less relevant for those working outside of the UK and Canada, where modelling 
practices may be different. Greater insight may have been permitted from further clinician interviews, as 
sampling was limited by the availability of clinicians in each case study, and it may be that their views and 
experiences are not representative of all clinical experts. Nevertheless, in-depth qualitative methods have 
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allowed detailed and novel insights to emerge, including through observation of communication between 
modellers and clinicians. Such an extensive investigation of real structural development processes has resulted 
in recommendations focusing on issues reported and observed to be most pertinent to those developing models 
[12]. 
4.3 Recommendations for practice and future research  
Findings suggest that a purposeful approach to sampling clinicians for structural development is optimal, aiming 
to achieve maximum variation in clinicians’ backgrounds relevant to the modelling context [34]. Sampling 
therefore focuses on the diversity of experts’ experiences, rather than maximising numbers, aligning with 
recommendations from expert elicitation studies [32, 33, 35] and acknowledging the recruitment difficulties 
reported. Modellers should make efforts to sample junior clinicians and those working outside of leading centres 
and professional links, to avoid correlation in clinicians’ views and to account for potentially different 
perspectives. The practicality of sampling clinicians outside of typical avenues is an important consideration for 
future research. Discussions between clinicians were observed to be valuable in identifying representative model 
pathways, and as such modelling processes may benefit from structured methods for gathering and managing 
multiple clinician perspectives. Possible approaches include qualitative focus groups [12] and the nominal group 
technique [32], which are both overseen by a moderator to avoid dominance and bias, and encourage individuals 
to reach consensus through consideration of each other’s views. 
The development of clinician training is an important area for future work, requiring further research to generate 
and evaluate ‘universal’ training content, with emphasis on the issues identified as important for guidance here. 
However, it is perhaps also worth considering the value of educating modellers in how to optimally present and 
gather information from clinical experts. Where time is limited, structural development may still benefit from 
modellers providing clinicians with a short history of decision-analytic modelling, explaining how structural 
pathways differ from clinical practice and providing regular updates on structural development using diagrams.  
It would be interesting to conduct further case studies to explore structural development in models where there 
are strong clinical advocates for the alternatives; where biases in pathway development may arise. Another 
important area for empirical research is exploring the methods and approaches modellers are using to elicit and 
aggregate quantitative evidence parameters from clinicians [35]. More broadly, qualitative research could 
explore other structural questions, such as how modellers incorporate clinicians’ views alongside information 
from other sources, including literature, other models and data availability.  
5 Conclusions 
This qualitative study has provided detailed insight into clinician involvement in structural development, 
highlighting key issues from modeller and clinician perspectives. Recommendations for modellers include 
recruiting clinicians from diverse backgrounds to encourage generalisable structures, and facilitating discussions 
between clinicians to generate robust and representative structural pathways. Future research should focus on 
clinician training to enhance efficiency of structural development processes, and investigate strategies for 
sampling clinicians outside of typical approaches. Steps to optimise clinician involvement can enhance the 
clinical validity of model structures and increase confidence in the decisions models inform.  
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Tables  
 
Table 1: Summary of modeller characteristics (in-depth interviews) 
 
 
 
Number 
of 
Informants 
(M1-M24) 
Gender 
of  
informant 
Nature of work Location of 
work 
Level of 
modelling 
experience 
Nature of role Number of 
models worked 
on 
Male 16 
 
Academic 16 UK 17 Senior 9 Supervisory 
only 
8 1-5 
models 
8 
Female 8 Non-
academic 
8 Canada 7 Junior 15 ‘Hands-on’ 
modelling  
10 6-15 
models 
5 
        Combination 
of both 
6 16+ 
models 
11 
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Table 2: Summary of case study characteristics and informants  
 Case study 
context 
Number of 
modellers in 
immediate 
structural 
development 
Nature/background of 
modellers 
Number/background 
of clinicians in 
immediate 
structural 
development 
Other (wider) 
modelling team 
members 
 
Case 
Study A 
(CSA) 
Academic, 
university 
setting, UK. 
Two (M25 and 
M26). 
M25 – Junior modeller, 
‘hands-on’ model 
development 
M26 – Senior modeller, 
supervisory role. 
One (C1). Chief 
Investigator for the 
clinical project and a 
specialist consultant 
with over ten years’ 
experience working 
for a local NHS 
hospital.  
C1 had no previous 
experience of health 
economic modelling.  
 
Additional modeller 
ad-hoc input. 
Broader team of 
clinical 
collaborators and 
statisticians. 
 
Case 
Study B 
(CSB) 
Policy 
institute, 
UK. 
Two (M27 and 
M28). 
M27 – Junior modeller, 
‘hands-on’ model 
development. 
M28 – Senior modeller, 
supervisory role 
Up to eleven per 
meeting (C2 – C12) – 
clinicians from 
different geographical 
locations and clinical 
roles. 
Three interviewed 
(C2, C3, and C4). All 
worked for NHS 
hospitals and had over 
ten years’ experience 
as consultants in 
respective 
specialisms.  
All had some 
previous exposure to 
modelling/projects 
with cost-
effectiveness element. 
 
Information 
specialists and 
project managers. 
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Table 3: Summary of results 
Summary of results 
Clinician recruitment: 
- Modellers described different processes for recruiting clinicians to structural development 
- Most UK academic, industry and policy modellers used formal methods: established projects/links  
- Using informal methods (UK/Canadian academics) made accessing clinicians difficult. 
Numbers and backgrounds of clinicians:  
- Numbers varied according to the context of modellers’ work and the nature of the project  
- Several modellers (n=6) and Case Study A worked on projects with only one clinician  
- Modellers emphasised the importance of working with senior or “key” clinicians. 
Problems with clinician involvement:  
Clinician numbers: 
- Modellers discussed problems with structural generalisability with only one clinician  
- In Case Study A, one clinician struggled to decide on representative pathways to inform structure 
- Diversity of clinician experience was not acknowledged as important by most modeller informants 
Clinician understanding:  
- Modellers encountered difficulties with retrieving information from clinicians to inform structure 
- Clinicians did not communicate ‘important’ events which could impact cost-effectiveness  
- Clinicians struggled with interpretation of terminology used by modellers during discussions. 
Recommendations from the research: 
- Discussions between multiple clinicians is valuable in developing representative structures  
- Clinicians should be recruited from diverse backgrounds to enhance structural generalisability  
- Structural processes would benefit from training clinicians in modelling. 
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Table 4: Number of clinicians typically involved in structural development (reported by 
interview informants in phase one) 
Number of clinicians worked with on any project Number of responses from informants 
0 clinicians 1 
1 clinician 6 
2 clinicians 11 
3 clinicians 7 
4 clinicians 5 
5 - 9 clinicians 2 
10 - 12 clinicians 6 
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Appendix 1: Interview topic guide for in-depth interviews with modellers (phase one) 
Experience of modelling 
• How did you begin? 
• What is your current role? What does it involve? 
• Have you worked on many models? 
• What type of modelling have you done previously? Disease areas? Model types? 
General modelling questions 
• How would you define the structure of a model? What are the boundaries? 
• What would you define as a ‘good’ modelling outcome? 
Examples of modelling activity  
• Can you think of an example of a model which you have worked on, where the development process 
was done particularly well?  
• Can you think of any examples of modelling processes which contrast with this? 
• Have you found the process easier/harder depending on the particular disease area that you are working 
in? 
• Have you found the process easier/harder depending on the clinician(s) that you speak to? The number 
of clinicians that you speak to? 
• Do you think that there is an ideal way to model? 
Model-building guidance  
• Do you or have you ever used modelling guidance to assist you in model building? Which guidance? 
How did you use it? 
• What do you think to the published modelling guidance as a whole? 
Model building process 
• Can you talk me through the process by which you usually develop the structure of a decision-analytic 
model? Why do you include [x] stage? Are there any other stages that you could include? 
• Do you speak to clinicians? How many? At what stage(s)? How do you ‘recruit’ them? 
• What model checking activities are carried out? In terms of the model structure?  
 20 
 
• Have you worked in modelling teams where this process is done differently? 
Future research  
• Which aspects of the model building process do you think require further investigation [for the purpose 
of developing best practice guidance]? 
• Can you think of teams of modellers who would provide interesting case studies for the purpose of this 
research? 
Finish 
• Anything else that you would like to contribute? 
 
